mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
I Sebastianutto, MA Cenci - Current Opinion in Pharmacology, 2018 - Elsevier
Highlights•Targeting specific mGluRs normalizes excessive glutamate/GABA transmission in
PD and LID models.•mGluR5 NAMs normalise biochemical and molecular changes
underlying LID.•mGluR5 NAMs show promising results in early clinical trials for the treatment
of LID.•Systemically active mGluR4 PAMs can potentiate the antiakinetic action of L-
DOPA.•The first-ever clinical trial of a mGluR4 PAM in PD is currently ongoing.Parkinson's
disease (PD) is a neurodegenerative disorder characterized by typical motor features that …
PD and LID models.•mGluR5 NAMs normalise biochemical and molecular changes
underlying LID.•mGluR5 NAMs show promising results in early clinical trials for the treatment
of LID.•Systemically active mGluR4 PAMs can potentiate the antiakinetic action of L-
DOPA.•The first-ever clinical trial of a mGluR4 PAM in PD is currently ongoing.Parkinson's
disease (PD) is a neurodegenerative disorder characterized by typical motor features that …